STRM.BIO
Cambridge
About STRM.BIO
STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy in a more efficient, safe, and practical manner. STRM.BIO aims to fulfill the promise of gene therapy by using extracellular vesicles to deliver treatment directly to the patient. The natural carriers of nucleic acids and proteins with innate targeting capabilities, the ability to be mass-produced on a large scale commercially, and low immunogenicity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.1M
- Funding stage: Seed
- Last round: Seed (Jan 2026)
- Website: strm.bio
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/strm-bio-122974 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.